EUVIMEDEUVIMED entdecken
Open Access

Genome-wide CRISPR screen identifies splicing factor SF3B4 in driving hepatocellular carcinoma

Yue Guo iD, Mingjing Xu iD, Hua Xue, Xiaofan Ding, Alissa M Wong iD, Na Lin iD, Dandan Pu iD, Aikha M Wong, Xin Wang iD, Hui Zhao iD, Nathalie Wong iD

Science Advances · 2025

DOI: 10.1126/sciadv.adw7181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Yue Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Sir Y.K. Pao Centre for Cancer, The Chinese University of Hong Kong, Shatin, Hong Kong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, RNA Splicing Factors, CRISPR-Cas Systems. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although genome sequencings have recognized many cancer-associated genes in hepatocellular carcinoma (HCC), distinguishing their functional effect remains challenging. Leveraging on a genome-wide CRISPR knockout (KO) screening, we uncovered spliceosome factors as major survival essential genes in HCC and up-regulations of ferroptosis suppressors [particularly glutamate-cysteine ligase catalytic subunit (GCLC)] in lenvatinib resistance. Our KO screen in patient-derived HCC organoid showed splicing factor 3b subunit 4 (SF3B4) to be top-ranked, conferring prosurvival signal in HCC organoid and driving tumorigenic potentials in both hepatic progenitor organoids and hydrodynamic tail vein injection HCC murine model. The combined RNA immunoprecipitation sequencing, long-read isoform sequencing, and transcriptome revealed characteristic splicing landscape regulated by SF3B4 and identified T-box transcription factor 3 (TBX3) variant TBX3+2a as a potent downstream effector. Our findings highlighted vital roles of SF3B4 in HCC cell survival and tumor progression, and the phenomenon of ferroptosis resistance in patients unresponsive to first-line agent lenvatinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsRNA Splicing FactorsCRISPR-Cas SystemsClustered Regularly Interspaced Short Palindromic RepeatsHumansAnimalsMiceFerroptosisGene Expression Regulation, NeoplasticCell Line, TumorPhenylurea CompoundsDrug Resistance, NeoplasmT-Box Domain ProteinsQuinolines

Substanzen

RNA Splicing FactorslenvatinibPhenylurea CompoundsT-Box Domain ProteinsQuinolines

Autor:innen und Institutionen

  • Department of Surgery, Sir Y.K. Pao Centre for Cancer, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
  • Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Taipa, Macao, China.
  • Key Laboratory for Regenerative Medicine, Ministry of Education, School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
  • State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

ORCID-Profile: Yue Guo, Mingjing Xu, Alissa M Wong, Na Lin, Dandan Pu, Xin Wang, Hui Zhao, Nathalie Wong

Zitieren

APA

Guo, Y., Xu, M., Xue, H., Ding, X., Wong, A. M., Lin, N., Pu, D., Wong, A. M., Wang, X., Zhao, H., & Wong, N. (2025). Genome-wide CRISPR screen identifies splicing factor SF3B4 in driving hepatocellular carcinoma. Science Advances. https://doi.org/10.1126/sciadv.adw7181

Vancouver

Guo Y, Xu M, Xue H, Ding X, Wong AM, Lin N, et al. Genome-wide CRISPR screen identifies splicing factor SF3B4 in driving hepatocellular carcinoma. Science Advances. 2025. doi:10.1126/sciadv.adw7181

BibTeX
@article{Guo2025,
  author = {Guo, Yue and Xu, Mingjing and Xue, Hua and Ding, Xiaofan and Wong, Alissa M and Lin, Na and Pu, Dandan and Wong, Aikha M and Wang, Xin and Zhao, Hui and Wong, Nathalie},
  title = {Genome-wide CRISPR screen identifies splicing factor SF3B4 in driving hepatocellular carcinoma},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adw7181}
}
Kostenlos starten →